Cooley M&A

JANUARY 25, 2023

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 23, 2024

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. Big pharma dominated life sciences M&A, with more than two-thirds (69%) of M&A investment coming from big pharma, compared to just 38% in 2022.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

M&A Leadership Council

JUNE 12, 2023

Insights & Advice: An Interview with Two Experts By Mark Herndon, Chairman Emeritus, M&A Leadership Council Cybersecurity and IT due diligence has become one of the most challenging, and also one of the most critical areas of due diligence in any environment. Tell us more about that. What is the business trying to accomplish?

IT 52

IT M&A Securities Insurance 52

Peak Frameworks

SEPTEMBER 19, 2023

For example, in the 2012 Facebook IPO, common shareholders gained exposure to the tech giant's fortunes, while also securing a say in corporate matters. The distinction between them is crucial for understanding a company's obligations, its strategy, and the interplay of interests within its ecosystem. What is a Shareholder?

Corporation 52

Corporation Private Equity Mergers and Acquisitions Corporate Finance 52

M&A Leadership Council

SEPTEMBER 9, 2021

By Mark Herndon, Chairman, M&A Leadership Council . The risks of brand damage, customer churn, and substantial costs have brought this topic to the forefront in many recent M&A Leadership Council workshops. Tell us more about that. Mark Dickelman (MD): Start by understanding the value proposition of the deal itself.

IT 52

IT M&A Securities Insurance 52

Mergers and Inquisitions

NOVEMBER 1, 2023

When you hear the words “healthcare private equity,” two thoughts probably come to mind: Wait a minute, isn’t healthcare a risky/growth-oriented sector? Why do PE firms operate there? Don’t they need companies with stable cash flows? In most of the world, healthcare is either government-run or a mixed public/private sector. For example, in the U.S.,

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

Cooley M&A

JANUARY 22, 2021

General Trends in Life Sciences M&A. In contrast, aggregate M&A deal value for the life sciences sector was down nearly 50% when compared to 2019, with the first half of 2020 particularly dismal in the wake of market uncertainty caused by the pandemic.

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40